Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia

Bala Sai Sundarasetty, Vijay Kumar Singh, Gustavo Salguero, Robert Geffers, Mareike Rickmann, Laura MacKe, Sylvia Borchers, Constanca Figueiredo, Axel Schambach, Urban Gullberg, Elena Provasi, Chiara Bonini, Arnold Ganser, Thomas Woelfel, Renata Stripecke

Research output: Contribution to journalArticle

Abstract

Wilms' tumor 1 antigen (WT1) is overexpressed in acute myeloid leukemia (AML), a high-risk neoplasm warranting development of novel immunotherapeutic approaches. Unfortunately, clinical immunotherapeutic use of WT1 peptides against AML has been inconclusive. With the rationale of stimulating multiantigenic responses against WT1, we genetically programmed long-lasting dendritic cells capable of producing and processing endogenous WT1 epitopes. A tricistronic lentiviral vector co-expressing a truncated form of WT1 (lacking the DNA-binding domain), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-4 (IL-4) was used to transduce human monocytes ex vivo. Overnight transduction induced self-differentiation of monocytes into immunophenotypically stable "SmartDC/tWT1" (GM-CSF+, IL-4+, tWT1+, IL-6+, IL-8+, TNF-α+, MCP-1+, HLA-DR+, CD86 +, CCR2+, CCR5+) that were viable for 3 weeks in vitro. SmartDC/tWT1 were produced with peripheral blood mononuclear cells (PBMC) obtained from an FLT3-ITD+ AML patient and surplus material from a donor lymphocyte infusion (DLI) and used to expand CD8+ T cells in vitro. Expanded cytotoxic T lymphocytes (CTLs) showed antigen-specific reactivity against WT1 and against WT1+ leukemia cells. SmartDC/tWT1 injected s.c. into Nod.Rag1-/-.IL2rγc-/- mice were viable in vivo for more than three weeks. Migration of human T cells (huCTLs) to the immunization site was demonstrated following adoptive transfer of huCTLs into mice immunized with SmartDC/tWT1. Furthermore, SmartDC/tWT1 immunization plus adoptive transfer of T cells reactive against WT1 into mice resulted in growth arrest of a WT1+ tumor. Gene array analyses of SmartDC/tWT1 demonstrated upregulation of several genes related to innate immunity. Thus, SmartDC/tWT1 can be produced in a single day of ex vivo gene transfer, are highly viable in vivo, and have great potential for use as immunotherapy against malignant transformation overexpressing WT1.

Original languageEnglish
Pages (from-to)220-237
Number of pages18
JournalHuman Gene Therapy
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 1 2013

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this

    Sundarasetty, B. S., Singh, V. K., Salguero, G., Geffers, R., Rickmann, M., MacKe, L., Borchers, S., Figueiredo, C., Schambach, A., Gullberg, U., Provasi, E., Bonini, C., Ganser, A., Woelfel, T., & Stripecke, R. (2013). Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia. Human Gene Therapy, 24(2), 220-237. https://doi.org/10.1089/hum.2012.128